Diagnostic and pharmaco-therapeutic options in acute severe blood loss;Diagnostische en farmacotherapeutische opties bij acuut ernstig bloedverlies

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 39, 2004, Pages 1907-1911

  Kamphuisen, P W ^a,b   Levi, M ^c   Van Kraaij, M G J ^a   Kaasjager, H A H ^d   Frolke J P M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PERUGIA   (Italy)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID;

ACUTE DISEASE; ALGORITHM; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL EXAMINATION; DISEASE SEVERITY; DRUG CHOICE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HEMOSTASIS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION; TREATMENT PLANNING;

ACUTE DISEASE; BLOOD TRANSFUSION; CRITICAL CARE; CRITICAL ILLNESS; HEMORRHAGE; HEMOSTASIS; HEMOSTATICS; HUMANS;

EID: 4644352904     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Pryor JP, Reilly PM. Initial care of the patient with blunt polytrauma. Clin Orthop 2004;422:30-6.
2. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.
3. Domen RE, Kennedy MS, Jones LL, Senhauser DA. Hemostatic imbalances produced by plasma exchange. Transfusion 1984;24:336-9.
4. Jonge E de, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-7.
5. Lim RC, Olcott C, Robinson AJ. Platelet response and coagulation changes following massive blood replacement. J Trauma 1973;18:577-81.
6. Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003;138:W15-24.
7. Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69-75.
8. Dorman BH, Spinale FG, Bailey MK, Kratz JM, Roy RC. Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thromboelastography versus coagulation screen. Anesth Analg 1993;76:694-700.
9. Poortman P, Meeuwis JD, Leenen LP. Multitrauma patiënten: principes van 'damage control surgery'. Ned Tijdschr Geneeskd 2000;144:1337-41.
10. Herwaarden JA van, Vroonhoven TJ van. Abdominal packing for surgically uncontrollable hemorrhage in ruptured abdominal aortic aneurysm repair. J Vasc Surg 2001;33:195-6.
11. Krige JE, Bomman PC, Terblanche J. Therapeutic perihepatic packing in complex liver trauma. Br J Surg 1992;79:43-6.
12. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Bloed-transfusie. Alphen aan den Rijn: Van Zuiden Communications; 2004. p. 203-5.
13. Kushimoto S, Arai M, Aiboshi J, Harada N, Tosaka N, Koido Y, et al. The role of interventional radiology in patients requiring damage control laparotomy. J Trauma 2003;54:171-6.
14. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002;287:1968-71.
15. Greenburg AG. Benefits and risks of blood transfusion in surgical patients. World J Surg 1996;20:1189-93.
16. Levi M, Koopman MM, Briët E. Farmacotherapeutische mogelijkheden voor correctie van stoornissen in de primaire hemostase. Ned Tijdschr Geneeskd 1999;143:347-51.
17. Sheridan DP, Card RT, Pinilla JC, Harding SM, Thomson DJ, Gauthier L, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetyl-salicylic-acid-induced platelet dysfunction. Can J Surg 1994;37:33-6.
18. Gratz I, Koehler J, Olsen D, Afshar M, DeCastro N, Spagna PM, et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992;104:1417-22.
19. Levi M, Cromheecke ME, Jonge E de, Prins MH, Mol BJ de, Briët E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7.
20. Levi M, Friederich PW, Meer J van der. Behandeling en preventie van bloedingen met recombinant-geactiveerde-factor VII, niet alleen bij hemofilie. Ned Tijdschr Geneeskd 2002;146:2534-7.
21. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-5.
22. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003;43:1711-6.
23. Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Haematol 2001;38:48-50.
24. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005-32.
25. Ekback G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckstrom J, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000;91:1124-30.
26. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043-8.
27. Engqvist A, Brostrom O, Feilitzen Fvon, Halldin M, Nystrom B, Ost A, et al. Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study. Scand J Gastroenterol 1979;14:839-44.
28. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000;355:1303-9.
29. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:1083-91.
30. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997;113:194-201.
31. Frölke JPM, Kamphuisen PW, Geeraedts jr LMG, Eijk RJ, Verwiel JMM, Kaasjager HAH. 'Blind' transfusiebeleid bij patiënten met acuut ernstig bloedverlies. Ned Tijdschr Geneeskd 2004;148:1901-6.
32. Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion [Cochrane review]. In: Cochrane Library. Issue 2. Oxford: Update Software; 2002.
33. Goodnough LT, Despotis GJ. Future directions in utilization review: the role of transfusion algorithms. Transfus Sci 1998;19:97-105.